ArticleCancer reports (Hoboken, N.J.)2025
Immunophenotypic Profiling of Acute Promyelocytic Leukemia: Insights From a Large Cohort.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical Management.Hematology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute promyelocytic leukemia (APL) is a highly aggressive disease that requires early initial therapy. Rapid diagnosis by flow cytometry remains the mainstay of initial diagnosis. However, the complexity of its immunochemistry has led to diagnostic uncertainty. METHODS AND
resultsWe comprehensively reviewed 2124 AML patients, with 170 classified as APL. In the univariate analysis, HLA-DR, CD34, CD56, CD11b, and CD11c were predominantly positive in the non-APL group compared to the APL group, while MPO and CD33 were significantly positive in the APL group. In the multivariate analysis, MPO was identified as a significantly higher positive marker in APL patients, while HLA-DR, CD34, and CD56 predicted non-APL patients. The typical immunophenotype of APL, including MPO+/HLA-DR-/CD34- and CD117+, provided a sensitivity of 51.4%, a specificity of 98.0%, a positive predictive value of 65.8%, and a negative predictive value of 96.5%. By utilizing the decision tree methodology, HLA-DR, MPO, and CD34 emerged as pivotal indicators for APL diagnosis within this model. Notably, HLA-DR took precedence, followed by MPO and CD34. Ultimately, a predictive equation for APL diagnosis was proposed to simplify the diagnosis of APL by flow cytometry using the positivity of HLA-DR, MPO, and CD34 as reference points.
conclusionThis study underscores the role of immunophenotyping as a rapid and complementary tool to molecular diagnostics, aiding in the preliminary identification of probable APL cases and facilitating timely initiation of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.